Better Buy in 2026: Pfizer or Merck?
(NYSE: PFE) and (NYSE: MRK) are two pharmaceutical giants that have lagged broader equities this year. Both have delivered unimpressive financial results recently, and are facing a somewhat uncertain medium-term outlook as they seek ways to navigate upcoming patent cliffs.
Both could make significant progress toward that goal in 2026, but which one is the better option for investors heading into the new year? Let's find out.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Stock
€21.64
-0.800%
With 14 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 27 € there is a positive potential of 24.8% for Pfizer Inc. compared to the current price of 21.64 €.
